Coronary Artery Disease Progression
Conditions
Brief summary
This study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.
Interventions
None listed
Sponsors
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed with heterozygous familial hypercholesterolemia * Adult between 18 and 50 years old * LDL cholesterol levels above 100 mg/dl (\>2.6 mmol/L) at inclusion
Exclusion criteria
* Renal insufficiency, defined as eGFR \< 30 ml/min * History of atherosclerotic cardiovascular events * Atrial fibrillation * Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator * Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CAD Progression | 40 Weeks | Difference in total plaque volume between the initial and follow-up CCTA scan |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Non-calcified plaque progression | 40 Weeks | Difference in non-calcified plaque volume between the baseline and follow-up CCTA scan |
| Calcified plaque progression | 40 Weeks | Difference in calcified plaque volume between the baseline and follow-up CCTA scan |
| Number of high-risk plaques | 40 Weeks | Difference in number of high-risk plaques between the baseline and follow-up CCTA scan |
| Difference in Pericoronary Adipose Tissue Attenuation | 40 Weeks | Difference in Pericoronary Adipose Tissue Attenuation between the baseline and follow-up CCTA scan |
Countries
Netherlands
Contacts
Primary ContactErik SG Stroes, MD, PhD
Outcome results
None listed